Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/INF.0000000000000709PMID 26069949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Centre for Disease Prevention and Control.

  2014cited by this paper
• DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe.

  2014cited by this paper
• DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe

  2013cited by this paper
• Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

  2013cited by this paper
• Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

  2012cited by this paper
• H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

  2012cited by this paper
• AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

  2012cited by this paper
• Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza.

  2012cited by this paper
• Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china

  2011cited by this paper
• Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

  2011cited by this paper
• Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England

  2011cited by this paper
• Low Vitamin D in Narcolepsy with Cataplexy

  2011cited by this paper
• Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain.

  2011cited by this paper
• AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.

  2010cited by this paper
• Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

  2010cited by this paper
• Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

  2010cited by this paper
• Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

  2010cited by this paper
• Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years: A Phase II, Randomized, Open, Controlled Study

  2010cited by this paper
• European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy.

  2010cited by this paper
• Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

  2010cited by this paper
• Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

  2010cited by this paper
• Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset.

  2009cited by this paper
• A novel influenza A (H1N1) vaccine in various age groups.

  2009cited by this paper
• Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  2009cited by this paper
• Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data

  2009cited by this paper
• Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.

  2009cited by this paper
• Social contact networks for the spread of pandemic influenza in children and teenagers

  2008cited by this paper
• Narcolepsy with cataplexy.

  2007cited by this paper
• Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

  2004cited by this paper
• Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

  1999cited by this paper

• The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.

  2024cites this paper
• Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.

  2021cites this paper
• Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model

  2020cites this paper
• Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice

  2018cites this paper
• Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials

  2017cites this paper
• [Influenza vaccination. Effectiveness of current vaccines and future challenges].

  2015cites this paper
• Vacunación antigripal. Efectividad de las vacunas actuales y retos de futuro

  2015cites this paper